Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace®). Preliminary data indicate equal efficacy and equal toxicity of these two hormones and suggests that both are suitable for first-line hormonal treatment of stage IV breast cancer.
|Original language||English (US)|
|Number of pages||4|
|Journal||Seminars in oncology|
|Issue number||4 SUPPL. 6|
|State||Published - Dec 1985|
ASJC Scopus subject areas